158 related articles for article (PubMed ID: 24461289)
1. Benzimidazole CB2 agonists: design, synthesis and SAR.
Nanda KK; Henze DA; Della Penna K; Desai R; Leitl M; Lemaire W; White RB; Yeh S; Brouillette JN; Hartman GD; Bilodeau MT; Trotter BW
Bioorg Med Chem Lett; 2014 Feb; 24(4):1218-21. PubMed ID: 24461289
[TBL] [Abstract][Full Text] [Related]
2. The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives.
Omura H; Kawai M; Shima A; Iwata Y; Ito F; Masuda T; Ohta A; Makita N; Omoto K; Sugimoto H; Kikuchi A; Iwata H; Ando K
Bioorg Med Chem Lett; 2008 Jun; 18(11):3310-4. PubMed ID: 18440813
[TBL] [Abstract][Full Text] [Related]
3. 5-Sulfonyl-benzimidazoles as selective CB2 agonists.
Verbist BM; De Cleyn MA; Surkyn M; Fraiponts E; Aerssens J; Nijsen MJ; Gijsen HJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2574-9. PubMed ID: 18394887
[TBL] [Abstract][Full Text] [Related]
4. Novel benzimidazole derivatives as selective CB2 agonists.
Pagé D; Balaux E; Boisvert L; Liu Z; Milburn C; Tremblay M; Wei Z; Woo S; Luo X; Cheng YX; Yang H; Srivastava S; Zhou F; Brown W; Tomaszewski M; Walpole C; Hodzic L; St-Onge S; Godbout C; Salois D; Payza K
Bioorg Med Chem Lett; 2008 Jul; 18(13):3695-700. PubMed ID: 18522867
[TBL] [Abstract][Full Text] [Related]
5. 5-sulfonyl-benzimidazoles as selective CB2 agonists-part 2.
Gijsen HJ; De Cleyn MA; Surkyn M; Van Lommen GR; Verbist BM; Nijsen MJ; Meert T; Wauwe JV; Aerssens J
Bioorg Med Chem Lett; 2012 Jan; 22(1):547-52. PubMed ID: 22130134
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB₂R selective benzimidazoles reveal unexpected intrinsic properties.
Nimczick M; Pemp D; Darras FH; Chen X; Heilmann J; Decker M
Bioorg Med Chem; 2014 Aug; 22(15):3938-46. PubMed ID: 24984935
[TBL] [Abstract][Full Text] [Related]
7. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
Ermann M; Riether D; Walker ER; Mushi IF; Jenkins JE; Noya-Marino B; Brewer ML; Taylor MG; Amouzegh P; East SP; Dymock BW; Gemkow MJ; Kahrs AF; Ebneth A; Löbbe S; O'Shea K; Shih DT; Thomson D
Bioorg Med Chem Lett; 2008 Mar; 18(5):1725-9. PubMed ID: 18255291
[TBL] [Abstract][Full Text] [Related]
8. Optimisation of a novel series of selective CNS penetrant CB(2) agonists.
Watson C; Owen DR; Harding D; Kon-I K; Lewis ML; Mason HJ; Matsumizu M; Mukaiyama T; Rodriguez-Lens M; Shima A; Takeuchi M; Tran I; Young T
Bioorg Med Chem Lett; 2011 Jul; 21(14):4284-7. PubMed ID: 21669533
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists.
Pizzi DA; Leslie CP; Mazzali A; Seri C; Biagetti M; Bentley J; Genski T; Di Fabio R; Contini S; Sabbatini FM; Zonzini L; Caberlotto L
Bioorg Med Chem Lett; 2010 Dec; 20(23):7120-3. PubMed ID: 20951033
[TBL] [Abstract][Full Text] [Related]
10. 2-Amino-5-aryl-pyridines as selective CB2 agonists: synthesis and investigation of structure-activity relationships.
Gleave RJ; Beswick PJ; Brown AJ; Giblin GM; Haslam CP; Livermore D; Moses A; Nicholson NH; Page LW; Slingsby B; Swarbrick ME
Bioorg Med Chem Lett; 2009 Dec; 19(23):6578-81. PubMed ID: 19864133
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor.
Romero-Parra J; Mella-Raipán J; Palmieri V; Allarà M; Torres MJ; Pessoa-Mahana H; Iturriaga-Vásquez P; Escobar R; Faúndez M; Di Marzo V; Pessoa-Mahana CD
Eur J Med Chem; 2016 Nov; 124():17-35. PubMed ID: 27560280
[TBL] [Abstract][Full Text] [Related]
12. CoMFA and CoMSIA analyses on 1,2,3,4-tetrahydropyrrolo[3,4-b]indole and benzimidazole derivatives as selective CB2 receptor agonists.
Cichero E; Cesarini S; Mosti L; Fossa P
J Mol Model; 2010 Sep; 16(9):1481-98. PubMed ID: 20174844
[TBL] [Abstract][Full Text] [Related]
13. Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.
Marx IE; DiMauro EF; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Human J; Lee JH; Li X; Martin MW; White RD; Fremeau RT; Patel VF
Bioorg Med Chem Lett; 2009 Jan; 19(1):31-5. PubMed ID: 19062274
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists.
Aghazadeh Tabrizi M; Baraldi PG; Ruggiero E; Saponaro G; Baraldi S; Poli G; Tuccinardi T; Ravani A; Vincenzi F; Borea PA; Varani K
Eur J Med Chem; 2016 May; 113():11-27. PubMed ID: 26922225
[TBL] [Abstract][Full Text] [Related]
15. Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases.
McBride CM; Renhowe PA; Heise C; Jansen JM; Lapointe G; Ma S; Piñeda R; Vora J; Wiesmann M; Shafer CM
Bioorg Med Chem Lett; 2006 Jul; 16(13):3595-9. PubMed ID: 16603352
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Han S; Thatte J; Buzard DJ; Jones RM
J Med Chem; 2013 Nov; 56(21):8224-56. PubMed ID: 23865723
[TBL] [Abstract][Full Text] [Related]
18. Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation.
Debenham JS; Madsen-Duggan CB; Wang J; Tong X; Lao J; Fong TM; Schaeffer MT; Xiao JC; Huang CC; Shen CP; Sloan Stribling D; Shearman LP; Strack AM; Euan Macintyre D; Hale JJ; Walsh TF
Bioorg Med Chem Lett; 2009 May; 19(9):2591-4. PubMed ID: 19328684
[TBL] [Abstract][Full Text] [Related]
19. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
Diaz P; Phatak SS; Xu J; Astruc-Diaz F; Cavasotto CN; Naguib M
J Med Chem; 2009 Jan; 52(2):433-44. PubMed ID: 19115816
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
Raitio KH; Savinainen JR; Vepsäläinen J; Laitinen JT; Poso A; Järvinen T; Nevalainen T
J Med Chem; 2006 Mar; 49(6):2022-7. PubMed ID: 16539390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
